OCGN: Ocugen, Inc. Price to Earnings Adjusted for Growth Rate
The implementation of automated laboratories for rapid biomolecule analysis accelerates drug discovery, which is reflected in the PEG ratio for Ocugen, Inc. (OCGN), where the current figure stands at 0.00. The business relies on flexible supply chains via global plants, as well as a diversified portfolio of ophthalmology drugs and vaccines developed through international cooperation.
Metric breakdowns and analytics for Ocugen Corp (OCGN)
- market value and analyst target forecast:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
- net income and valuation multiples indicators:
OCGN - Net Profit|Future Profit Ocugen, Inc.|OCGN - P/E Multiple|Forward Price to Earnings Multiple ocugen.com|OCGN - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Ocugen Pharma|OCGN - Operating profit EBITDA|Earnings per share for the last 12 months Ocugen|OCGN - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months ocugen.com|OCGN - Earnings growth in current year|Earnings growth forecast for next year Ocugen, Inc.
- sales revenue and business income indicators:
General company analysis:OCGN (Ocugen, Inc.)
This indicator is calculated by dividing the P/E ratio by the earnings growth rate, determining the fairness of the market value relative to income dynamics. An analysis of the PEG ratio allows for an assessment of Ocugen, Inc. (OCGN) management efficiency against the backdrop of the biotech business's minimal environmental costs, identifying asset undervaluation by comparing expansion rates with the current quote.
Who Ocugen, Inc. competes with
PEG Multiple Tempus (TEM)|PEG Multiple QGEN (Qiagen NV)|Growth-Adjusted Market Cap to Net Income Ionis (IONS)|repligen.com - PEG Multiple|Price to Earnings Adjusted for Growth Rate Avidity|CRSP (CRISPR Therapeutics Corp) - Price/Earnings to Growth Multiple|GeneDx Corp - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Ultragenyx|Price to Earnings Adjusted for Growth Rate beamtx.com BEAM|Price/Earnings to Growth Multiple SRPT (Sarepta Therapeutics, Inc.)|TWST - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio 10x TXG|Company Value to Earnings Growth Ratio NTLA (Intellia)|Stoke Corp - PEG Multiple|BLFS: Price/Earnings to Growth Ratio|WVE: PEG Multiple|Price to Earnings Adjusted for Growth Rate Maze Tx (MAZE)|Price/Earnings to Growth Ratio Sionna Therapeutics|Growth-Adjusted P/E Ratio PRME (Prime Medicine Corp)|PEG Multiple TSHA|PEG Multiple uniqure.com (QURE)|Price/Earnings to Growth Ratio MeiraGTx PLC MGTX|Growth-Adjusted Payback Ratio RGNX|solidbio.com - PEG Multiple|PACB (Pacific Biosciences of California) - Growth-Adjusted P/E Ratio|BNTC: PEG Multiple|DSGN - Growth-Adjusted Market Cap to Net Income|RCKT (Rocket Pharma) - PEG Multiple|Price/Earnings to Growth Ratio FDMT|Price/Earnings to Growth Ratio Lexeo Therapeutics, Inc. (LXEO)|Korro Bio Inc. - Growth-Adjusted P/E Ratio|editasmedicine.com - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income silence-therapeutics.com (SLN)|PRQR: Price/Earnings to Growth Multiple|Price to Earnings Adjusted for Growth Rate codexis.com|SGMO: PEG Multiple|Price to Earnings Adjusted for Growth Rate Nautilus Biotechnology Inc (NAUT)|Price/Earnings to Growth Multiple MGX|DTIL (Precision BioSciences) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Ratio Generation Bio Corp (GBIO)|Boundless Bio - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Exicure, Inc. XCUR|Growth-Adjusted Payback Ratio IMNN|PHIO - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Mustang Bio Inc MBIO|RNAZ: PEG Multiple|Growth-Adjusted P/E Ratio BNGO|APDN (Applied DNA Sciences Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Bluebird Bio BLUE|PEG Multiple IPA|Omega Therapeutics (OMGA) - Price to Net Income Growth Ratio|PEG Multiple OMIC (Singular Genomics Systems Inc)|Price to Net Income Growth Ratio Regulus Therapeutics Inc|SYRS - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio TBIO (Codex DNA)|TCON: PEG Multiple|UBX - Growth-Adjusted Market Cap to Net Income
